Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of At-9283. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 12/20 | 0.71 |
| ▸ | AURKB known ✓ | Q96GD4 | 12/20 | 0.71 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.71 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.71 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.71 |
| ▸ | JAK3 known ✓ | P52333 | 1/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.71 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.71 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.71 |
| ▸ | KDR | P35968 | 3/20 | 0.71 |
| ▸ | FLT1 | P17948 | 2/20 | 0.71 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.71 |
| ▸ | CDC7 | O00311 | 1/20 | 0.71 |
| ▸ | PLK4 | O00444 | 1/20 | 0.71 |
| ▸ | STK25 | O00506 | 1/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.71 |
| ▸ | BUB1 | O43683 | 1/20 | 0.71 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| At-9283 SCHEMBL29353018 | 1.00 | AURKA (0.71) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL545810 | 0.94 | AURKA (0.64) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL545942 | 0.93 | AURKA (0.62) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL546034 | 0.93 | AURKA (0.61) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL546435 | 0.93 | AURKA (0.61) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| SCHEMBL10240197 | 0.91 | AURKA (0.63) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| SCHEMBL10240259 | 0.90 | AURKA (0.60) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL546065 | 0.90 | AURKA (0.58) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| SCHEMBL10240249 | 0.90 | AURKA (0.64) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL546031 | 0.89 | AURKA (0.57) | AURKAAURKBFGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4541381-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2026-02-04 | — | — | EP | disclosed |
| EP-4545101-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4541380-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| EP-4545100-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-12-09 | — | — | US | disclosed |
| EP-4541379-B1 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | ADVANCED ACCELERATOR APPLICATIONS S A (FR) | 2025-11-19 | — | — | EP | disclosed |
| EP-4640241-A2 | STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS | Advanced Accelerator Applications S.A. (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250295820-A1 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (IT) | 2025-09-25 | — | — | US | disclosed |
| US-12415003-B2 | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS SA (FR) | 2025-09-16 | — | — | US | disclosed |
| EP-4381284-B1 | LIGAND-TARGET INTERACTION ANALYSIS BY PHOTOCHEMICALLY INDUCED DYNAMIC NUCLEAR POLARIZATION (PHOTO-CIDNP) ENHANCED NMR SPECTROSCOPY | ETH ZUERICH (CH) | 2025-07-09 | — | — | EP | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008044045-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008001101-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001101-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001115-A2 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3- (5-M0RPHOOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL) -LH-1-PYRAZOL- 4-YL] -UREA | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001115-A2 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3- (5-M0RPHOOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL) -LH-1-PYRAZOL- 4-YL] -UREA | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| EP-1833819-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006070195-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415003-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | AURKA 1920/4885AURKB 2923/4885FLT3 1933/4885 |
| US-12491272-B2 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | AURKA 1920/4885AURKB 2923/4885FLT3 1933/4885 |
| US-20250295820-A1 | Stable, concentrated radionuclide complex solutions | EPOR, PAICS, XPO5 | AURKA 1920/4885AURKB 2923/4885FLT3 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.